Biomea Fusion, Inc. (BMEA)
0.5744
-0.01
(-2.38%)
USD |
NASDAQ |
Nov 20, 16:00
0.5663
-0.01
(-1.41%)
After-Hours: 20:00
Biomea Fusion Research and Development Expense (TTM) : 34.91M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 34.91M |
| June 30, 2026 | 40.78M |
| March 31, 2026 | 48.20M |
| December 31, 2025 | 61.98M |
| September 30, 2025 | 79.10M |
| June 30, 2025 | 91.95M |
| March 31, 2025 | 107.21M |
| December 31, 2024 | 118.08M |
| September 30, 2024 | 123.71M |
| June 30, 2024 | 121.81M |
| March 31, 2024 | 111.93M |
| December 31, 2023 | 102.55M |
| Date | Value |
|---|---|
| September 30, 2023 | 92.22M |
| June 30, 2023 | 85.11M |
| March 31, 2023 | 75.76M |
| December 31, 2022 | 62.71M |
| September 30, 2022 | 53.26M |
| June 30, 2022 | 42.91M |
| March 31, 2022 | 35.55M |
| December 31, 2021 | 28.00M |
| September 30, 2021 | 19.24M |
| June 30, 2021 | 12.14M |
| March 31, 2021 | 7.135M |
| December 31, 2020 | 3.671M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| REGENXBIO, Inc. | 219.05M |
| Compass Therapeutics, Inc. | 68.60M |
| ACADIA Pharmaceuticals, Inc. | 319.46M |
| Alnylam Pharmaceuticals, Inc. | 1.559B |
| Anika Therapeutics, Inc. | 28.40M |